Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.430
+0.070 (2.97%)
Jan 22, 2026, 2:52 PM EST - Market open
Spero Therapeutics Employees
Spero Therapeutics had 32 employees as of December 31, 2024. The number of employees decreased by 14 or -30.43% compared to the previous year.
Employees
32
Change (1Y)
-14
Growth (1Y)
-30.43%
Revenue / Employee
$1,267,156
Profits / Employee
-$1,369,875
Market Cap
136.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 32 | -14 | -30.43% |
| Dec 31, 2023 | 46 | 11 | 31.43% |
| Dec 31, 2022 | 35 | -111 | -76.03% |
| Dec 31, 2021 | 146 | 57 | 64.04% |
| Dec 31, 2020 | 89 | 32 | 56.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsSPRO News
- 4 weeks ago - Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - GlobeNewsWire
- 7 weeks ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - GlobeNewsWire
- 3 months ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire
- 3 months ago - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewsWire
- 5 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire